C34.81
C34.81 — Malignant neoplasm of overlapping sites of right bronchus and lung
Billable / specific codeICD-10-CMright
C34.81 is a billable, specific ICD-10-CM code for malignant neoplasm of overlapping sites of right bronchus and lung. It is valid for submission on a claim.
Risk adjustment
C34.81 risk-adjusts. Under the CMS-HCC V28 model it maps to this category:
- HCC 20 Lung and Other Severe Cancers1.136 RAF
Coefficient shown for the Community Non-dual Aged segment. A higher HCC in the same hierarchy will suppress this one, so capturing it does not always add score.
Medicare coverage
C34.81 is named in 100 Medicare coverage policies — 100 listing it as supporting medical necessity. Which of them applies to you depends on your Medicare contractor, and coverage genuinely differs by state.
- A52370Billing and Coding: Bevacizumab and biosimilars
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52450Billing and Coding: Paclitaxel (e.g., Taxol®/Abraxane ™)
- A52479Oral Anticancer Drugs - Policy Article
Related codes at this level
Codes that share C34.8. If C34.81 is not quite right, the correct code is usually one of these.
Questions about C34.81
- Is C34.81 a billable ICD-10-CM code?
- Yes. C34.81 is a billable, specific ICD-10-CM code and is valid for submission on a claim.
- Where does C34.81 sit in the tabular list?
- Neoplasms (C00-D49), in the block Malignant neoplasms of respiratory and intrathoracic organs (C30-C39).